Effector Therapeutics, Inc.

Theo Michels

Siegfried Heinz Reich

Chinh Viet Tran

Justin T Ernst

Garrick Kenneth Packard

Alan X Xiang

Paul A Sprengeler

Christian Nilewski

Samuel Sperry

Kaveri Urkalan

Mike Shaghafi

Alan Grubbs

Takasuke Mukaiyama

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.  For Formula I compounds X, Y, R, R, R, R, R, Rand Rare as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

EIF4A-inhibiting compounds and methods related thereto

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.  For Formula I compounds X, X, X, X, X, X, Q, L, L, Y, R, R, R, R, R, R, R, Rand rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

EIF4E-inhibiting compounds and methods

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R, R, R, R, R, Rand Rare as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

eIF4A-inhibiting compounds and methods related thereto

Growing community of inventors

San Diego, CA, United States of America

Theo Michels